Burkhard Blank Sells 11,050 Shares of Acorda Therapeutics, Inc. (ACOR) Stock

Acorda Therapeutics, Inc. (NASDAQ:ACOR) insider Burkhard Blank sold 11,050 shares of Acorda Therapeutics stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $20.53, for a total value of $226,856.50. Following the sale, the insider now directly owns 33,150 shares in the company, valued at $680,569.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Acorda Therapeutics, Inc. (ACOR) traded down $0.10 during midday trading on Thursday, hitting $20.35. The stock had a trading volume of 372,100 shares, compared to its average volume of 932,747. Acorda Therapeutics, Inc. has a 52-week low of $13.60 and a 52-week high of $33.00. The company has a quick ratio of 2.40, a current ratio of 2.77 and a debt-to-equity ratio of 0.49.

Acorda Therapeutics (NASDAQ:ACOR) last released its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.43 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.69 by ($0.26). The firm had revenue of $141.07 million for the quarter, compared to the consensus estimate of $150.64 million. Acorda Therapeutics had a negative net margin of 10.25% and a negative return on equity of 8.18%. The company’s revenue was up 4.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.04) EPS. equities analysts anticipate that Acorda Therapeutics, Inc. will post -0.07 earnings per share for the current fiscal year.

A number of analysts have recently commented on ACOR shares. Cowen reissued a “buy” rating and set a $35.00 price target on shares of Acorda Therapeutics in a research note on Tuesday, August 29th. Zacks Investment Research lowered Acorda Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, October 30th. Stifel Nicolaus reissued a “buy” rating and set a $26.00 price target (down from $30.00) on shares of Acorda Therapeutics in a research note on Thursday, August 31st. Goldman Sachs Group reissued a “sell” rating and set a $20.00 price target on shares of Acorda Therapeutics in a research note on Friday, October 6th. Finally, Janney Montgomery Scott reissued a “hold” rating and set a $18.00 price target on shares of Acorda Therapeutics in a research note on Wednesday, August 30th. Four analysts have rated the stock with a sell rating, eleven have issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $21.47.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State of Wisconsin Investment Board bought a new stake in shares of Acorda Therapeutics during the second quarter valued at approximately $630,000. Dimensional Fund Advisors LP increased its holdings in shares of Acorda Therapeutics by 29.6% during the second quarter. Dimensional Fund Advisors LP now owns 2,372,868 shares of the biopharmaceutical company’s stock valued at $46,745,000 after acquiring an additional 541,418 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Acorda Therapeutics by 306.8% during the second quarter. Goldman Sachs Group Inc. now owns 534,956 shares of the biopharmaceutical company’s stock valued at $10,538,000 after acquiring an additional 403,467 shares in the last quarter. Teachers Advisors LLC increased its holdings in shares of Acorda Therapeutics by 8.0% during the second quarter. Teachers Advisors LLC now owns 78,886 shares of the biopharmaceutical company’s stock valued at $1,554,000 after acquiring an additional 5,837 shares in the last quarter. Finally, State Street Corp increased its holdings in shares of Acorda Therapeutics by 52.4% during the second quarter. State Street Corp now owns 2,476,033 shares of the biopharmaceutical company’s stock valued at $48,783,000 after acquiring an additional 851,290 shares in the last quarter.

TRADEMARK VIOLATION NOTICE: This article was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.com-unik.info/2017/12/07/burkhard-blank-sells-11050-shares-of-acorda-therapeutics-inc-acor-stock.html.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

Insider Buying and Selling by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

What are top analysts saying about Acorda Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Acorda Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit